Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эндометриоз: патофизиология и выбор лечебной тактики
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Eskenazi B, Warner N. Epidemiology of endometriosis. Obstet Gynecol North Am 1997; 24: 235–58.
2. Witz C, Thomas M, Montoya-Rodriguez I et al. Short-term culture of peritoneum explants confirms attachment of endometrium to intact peritoneal mesothelium. Fertil Steril 2001; 75: 385–90.
3. Vercillini P, Aimi G, De Giorgi O et al. Is cystic ovarian endometriosis an asymmetric disease? Br J Obstet Gynecol 1998; 105: 1018–21.
4. Buletti C, DeZiegler D, Stefanetti M et al. Endometriosis: Absence of recurrence in patients after endometrial ablation. Hum Reprod 2001; 16: 2676–9.
5. Campbell I, Thomas E. Endometriosis: Candidate genes. Human Reprod Update 2001; 7: 15–20.
6. Bishoff F, Heard M, Simpson J. Somatic DNA alterations in endometriosis: High frequency of chromosome 17 and p53 loss in late stage endometriosis. J Reprod Immunol 2002; 55: 49–64.
7. Lebovic D, Baldocchi RA, Mueller MD et al. Altered expression of a cell-cycle suppressor gene, Tob-1, in endometriotic cells by cDNA array analyses. Fertil Steril 2002; 78: 849–54.
8. Taylor RN. Endometriosis. In: Strauss J.F. III, Barbieri R.L. (ed). Yen and Jaffe`s Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, 5th ed. Philadelphia: Elsevier Saunders, 2004; 691–711.
9. Герасимов А.М. Одно из звеньев патогенеза бесплодия при наружном генитальном эндометриозе. Пробл. репродук. 2004; 4: 35–9.
10. Chegini N. Peritoneal molecular environment, adhesion formation and clinical implication. Front Biosci 2002; 7: 91–115.
11. Dmowski W, Ding J, Shen J et al. Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis. Human Reprod 2001; 16: 1802–8.
12. Osteen K, Bruner-Tran K, On D et al. Paracrine mediators of endometrial matrix metalloproteinase expression: Potential targets for progestin-based treatment of endometriosis. Ann N Y Acad Sci 2002; 955: 139–46.
13. Van Kaam KJAF, Romano A, Schouten JP et al. Progesterone receptor polymorphism +331G/A is associated with a decreased risk of deep infiltrating endometriosis. Hum reprod 2007; 22 (1): 129–35.
14. Weaver F, Hynes D, Goldberg GM et al. Hysterectomy in Veterans Affairs Medical Centers. Obstet Gynecol 2001; 97: 880–4.
15. MacDonald SR, Klock SC, Milad MP. Long-term outcome of nonconservative surgery (hysterectomy) for endometriosis-associated pain in women <30 years old. Am J Obstet Gynecol 1999; 180: 1360–3.
16. Назарова А.О., Валькова А.В., Шарабанова И.Ю. и др. Состояние клеточных компонентов перитонеального микроокружения у крыс с экспериментальным эндометриозом и эффективность хирургического лечения. Пробл. репродук. 2004; 3: 12–5.
17. Тихомиров А.Л., Лубнин Д.М. Патогенетическое обоснование применения агонистов ГнРГ в терапии сочетанной гинекологической патологии. Вопр. гин., акуш. и перинатол. 2006; 5 (1): 82–7.
18. Лубнин Д.М., Тихомиров А.Л. Принципы лечения миомы матки: от агонистов ГнРГ до эмболизации маточных артерий. Вопр. гин., акуш. и перинатол. 2005; 4 (4): 76–82.
19. Ушакова Е.Л. Применение Люкрина депо при эндометриозе, миомематки и других заболеваниях. Бесплодный брак: Руководство для врачей. Под ред. В.И.Кулакова. М.: ГЭОТАР-Медиа, 2005; 30–7.
20. Бесплодный брак: Руководство для врачей. Под ред. В.И.Кулакова. М.: ГЭОТАР-Медиа, 2005.
21. Halbe HW, de Melo NR, Bahamondes L et al. Effucacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. Eur J Contracept Reprod Health Care 1998; 3: 113–20.
22. Thomas SL, Ellertsone C. Nuisanceor natural and healthy: should monthly menstruation be optional for women. Lancet 2000; 355: 922–24. desensitize mu-opioid receptors on dorsal root ganglia heurons. J Immunol 2004; 173: 594–9.
23. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002; 186: 1142–9.
24. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanism in inflammatory and neurophatic hyperalgesia. Neurosci Lett 2004; 361: 184–7.
25. Zhang N, Rogers TJ, Caterina M, Oppenheim JJ. Proinflamatory chemokines, such as C-C chemokine ligand 3.
26. Matsuzaki S, Canis M, Pouly J-L et al. Both GnRH agonist and continuous oral progestin treatments reduce the expression of the tyrosine kinase receptor B and mu-opioid receptor in deep infiltrating endometriosis. Hum Reprod 2007; 22 (1): 124–8.
27. Davis CJ, McMillan L. Pain in endometriosis: effectiveness of medical and surgical management. Curr Opin Obstet Gynecol 2003; 15: 507–12.
28. Kennedy S, Bergqvist A, Chapron C et al. ESHRE guidline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20: 2698–704.
2. Witz C, Thomas M, Montoya-Rodriguez I et al. Short-term culture of peritoneum explants confirms attachment of endometrium to intact peritoneal mesothelium. Fertil Steril 2001; 75: 385–90.
3. Vercillini P, Aimi G, De Giorgi O et al. Is cystic ovarian endometriosis an asymmetric disease? Br J Obstet Gynecol 1998; 105: 1018–21.
4. Buletti C, DeZiegler D, Stefanetti M et al. Endometriosis: Absence of recurrence in patients after endometrial ablation. Hum Reprod 2001; 16: 2676–9.
5. Campbell I, Thomas E. Endometriosis: Candidate genes. Human Reprod Update 2001; 7: 15–20.
6. Bishoff F, Heard M, Simpson J. Somatic DNA alterations in endometriosis: High frequency of chromosome 17 and p53 loss in late stage endometriosis. J Reprod Immunol 2002; 55: 49–64.
7. Lebovic D, Baldocchi RA, Mueller MD et al. Altered expression of a cell-cycle suppressor gene, Tob-1, in endometriotic cells by cDNA array analyses. Fertil Steril 2002; 78: 849–54.
8. Taylor RN. Endometriosis. In: Strauss J.F. III, Barbieri R.L. (ed). Yen and Jaffe`s Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, 5th ed. Philadelphia: Elsevier Saunders, 2004; 691–711.
9. Герасимов А.М. Одно из звеньев патогенеза бесплодия при наружном генитальном эндометриозе. Пробл. репродук. 2004; 4: 35–9.
10. Chegini N. Peritoneal molecular environment, adhesion formation and clinical implication. Front Biosci 2002; 7: 91–115.
11. Dmowski W, Ding J, Shen J et al. Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis. Human Reprod 2001; 16: 1802–8.
12. Osteen K, Bruner-Tran K, On D et al. Paracrine mediators of endometrial matrix metalloproteinase expression: Potential targets for progestin-based treatment of endometriosis. Ann N Y Acad Sci 2002; 955: 139–46.
13. Van Kaam KJAF, Romano A, Schouten JP et al. Progesterone receptor polymorphism +331G/A is associated with a decreased risk of deep infiltrating endometriosis. Hum reprod 2007; 22 (1): 129–35.
14. Weaver F, Hynes D, Goldberg GM et al. Hysterectomy in Veterans Affairs Medical Centers. Obstet Gynecol 2001; 97: 880–4.
15. MacDonald SR, Klock SC, Milad MP. Long-term outcome of nonconservative surgery (hysterectomy) for endometriosis-associated pain in women <30 years old. Am J Obstet Gynecol 1999; 180: 1360–3.
16. Назарова А.О., Валькова А.В., Шарабанова И.Ю. и др. Состояние клеточных компонентов перитонеального микроокружения у крыс с экспериментальным эндометриозом и эффективность хирургического лечения. Пробл. репродук. 2004; 3: 12–5.
17. Тихомиров А.Л., Лубнин Д.М. Патогенетическое обоснование применения агонистов ГнРГ в терапии сочетанной гинекологической патологии. Вопр. гин., акуш. и перинатол. 2006; 5 (1): 82–7.
18. Лубнин Д.М., Тихомиров А.Л. Принципы лечения миомы матки: от агонистов ГнРГ до эмболизации маточных артерий. Вопр. гин., акуш. и перинатол. 2005; 4 (4): 76–82.
19. Ушакова Е.Л. Применение Люкрина депо при эндометриозе, миомематки и других заболеваниях. Бесплодный брак: Руководство для врачей. Под ред. В.И.Кулакова. М.: ГЭОТАР-Медиа, 2005; 30–7.
20. Бесплодный брак: Руководство для врачей. Под ред. В.И.Кулакова. М.: ГЭОТАР-Медиа, 2005.
21. Halbe HW, de Melo NR, Bahamondes L et al. Effucacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. Eur J Contracept Reprod Health Care 1998; 3: 113–20.
22. Thomas SL, Ellertsone C. Nuisanceor natural and healthy: should monthly menstruation be optional for women. Lancet 2000; 355: 922–24. desensitize mu-opioid receptors on dorsal root ganglia heurons. J Immunol 2004; 173: 594–9.
23. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002; 186: 1142–9.
24. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanism in inflammatory and neurophatic hyperalgesia. Neurosci Lett 2004; 361: 184–7.
25. Zhang N, Rogers TJ, Caterina M, Oppenheim JJ. Proinflamatory chemokines, such as C-C chemokine ligand 3.
26. Matsuzaki S, Canis M, Pouly J-L et al. Both GnRH agonist and continuous oral progestin treatments reduce the expression of the tyrosine kinase receptor B and mu-opioid receptor in deep infiltrating endometriosis. Hum Reprod 2007; 22 (1): 124–8.
27. Davis CJ, McMillan L. Pain in endometriosis: effectiveness of medical and surgical management. Curr Opin Obstet Gynecol 2003; 15: 507–12.
28. Kennedy S, Bergqvist A, Chapron C et al. ESHRE guidline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20: 2698–704.
Авторы
И.В.Кузнецова
Кафедра акушерства и гинекологии №1 (зав. – проф А.И.Ищенко) лечебного факультета ММА им. И.М.Сеченова
Кафедра акушерства и гинекологии №1 (зав. – проф А.И.Ищенко) лечебного факультета ММА им. И.М.Сеченова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.